Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold

Malignant Pleural Mesothelioma (MPM) is a highly aggressive disease whose diagnosis could be challenging and confusing. It could occur with atypical presentations on every examined level. Here, we present three unconventional cases of the complex diagnostic process of MPM that we have experienced during routine practice: a patient with reactive mesothelial hyperplasia mimicking MPM, an unexpected presentation of MPM with persistent unilateral hydropneumothorax, a rare case of MPM in situ. Then, we review the relevant literature on each of these topics. Definitive biomarkers to confidently distinguish MPM from other pleural affections are still demanded. Patients presenting with persistent hydropneumothorax must always be investigated for MPM. MPM in situ is now a reality, and this raises questions about its management.

[1]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Migliore,et al.  Asbestos Exposure and Malignant Mesothelioma in Construction Workers—Epidemiological Remarks by the Italian National Mesothelioma Registry (ReNaM) , 2021, International journal of environmental research and public health.

[3]  N. Girard,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  G. Rossi,et al.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines , 2021, Journal of clinical medicine.

[5]  J. Creaney,et al.  Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology , 2021, Cytopathology : official journal of the British Society for Clinical Cytology.

[6]  S. Hakim,et al.  Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study , 2021, Pathology & Oncology Research.

[7]  G. Rossi,et al.  The “Brescia panel” (Claudin‐4 and BRCA‐associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas , 2020, Cancer cytopathology.

[8]  D. Henderson,et al.  Malignant mesothelioma in situ: diagnostic and clinical considerations. , 2020, Pathology.

[9]  F. Galateau-Sallé,et al.  ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. , 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  F. Galateau-Sallé,et al.  Malignant Mesothelioma In Situ: Clinical and Pathologic Implications. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  S. Armato,et al.  EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Y. Maniwa,et al.  Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report , 2019, Virchows Archiv.

[13]  F. Galateau-Sallé,et al.  Malignant mesothelioma in situ: morphologic features and clinical outcome , 2019, Modern Pathology.

[14]  F. Galateau-Sallé,et al.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy , 2019, CA: a cancer journal for clinicians.

[15]  L. Vimercati,et al.  Epidemiology of Mesothelioma , 2019, Environments.

[16]  R. Durrance,et al.  Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review☆ , 2018, Respiratory medicine case reports.

[17]  Z. Lv,et al.  Diagnostic accuracy of BRCA1–associated protein 1 in malignant mesothelioma: a meta-analysis , 2017, Oncotarget.

[18]  Y. Takeshima,et al.  Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma , 2017, Histopathology.

[19]  Nick A Maskell,et al.  Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment , 2016, European Respiratory Review.

[20]  F. Galateau-Sallé,et al.  Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). , 2016, Archives of pathology & laboratory medicine.

[21]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  G. Rossi,et al.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations , 2015, Modern Pathology.

[23]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations , 2015, The American journal of surgical pathology.

[24]  H. Saji,et al.  Malignant pleural mesothelioma presenting as a spontaneous pneumothorax , 2014, Respirology case reports.

[25]  John P Lichtenberger,et al.  Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  C. Comin,et al.  Expression of Thrombomodulin, Calretinin, Cytokeratin 5/6, D2–40 and WT-1 in a Series of Primary Carcinomas of the Lung: An Immunohistochemical Study in Comparison with Epithelioid Pleural Mesothelioma , 2014, Tumori.

[27]  P. Sriram,et al.  Malignant Mesothelioma Presenting as a Gradually Enlarging Pneumothorax , 2013, Case reports in pulmonology.

[28]  D. Henderson,et al.  Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA , 2013, Journal of Clinical Pathology.

[29]  D. Henderson,et al.  Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers , 2013, Journal of Clinical Pathology.

[30]  M. Muers,et al.  Pleural mesothelioma presenting as recurrent pneumothoraces. , 2010, British journal of hospital medicine.

[31]  J. Harvey,et al.  BTS guidelines for the management of spontaneous pneumothorax , 2003, Thorax.

[32]  S. Okushiba,et al.  Spontaneous Pneumothorax Secondary to Radiographically Occult Lung Metastasis from Parapharyngeal Synovial Sarcoma: Report of a Case , 2002, Surgery Today.

[33]  V. Roggli,et al.  Well-Differentiated Papillary Mesothelioma , 2001, The American journal of surgical pathology.

[34]  S. Markowitz,et al.  Malignant pleural mesothelioma presenting as spontaneous pneumothorax: a case series and review. , 2000, American journal of industrial medicine.

[35]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[36]  D. Henderson,et al.  The concept of mesothelioma in situ: implications for diagnosis and histogenesis. , 1992, Seminars in diagnostic pathology.

[37]  W. Taylor,et al.  Pneumothorax and malignant mesothelioma in patients over the age of 40. , 1991, Thorax.

[38]  H. Eisenstadt.  Malignant mesothelioma of the pleura. , 1956, Diseases of the Chest.

[39]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.